Sheena Jonathan, a co-founder and director at Natera, Inc. (NASDAQ:NTRA), executed a transaction involving the disposal of 3,150 shares of the company's common stock on July 13, 2026. The transaction resulted in proceeds totaling $836,898. The shares were sold at prices ranging from $262.716 to $268.387 per share. This divestment activity was conducted under the parameters of a Rule 10b5-1 trading plan, which Jonathan established on December 12, 2025.
Following the execution of these sales, Jonathan's direct holding in Natera common stock stands at 246,202 shares. Furthermore, 18,782 shares are held indirectly by the Caraluna 1 Trust, and an identical amount of 18,782 shares is held by the Caraluna 2 Trust. Jonathan has formally disclaimed beneficial ownership over the securities held within these trusts.
The stock sale occurs against a backdrop of significant price appreciation for Natera. The shares were trading at $277.44 at the time of the report, which is 3.7% below the 52-week high of $288.04. Over the preceding year, the stock has recorded an 87% gain. According to valuation analysis provided by InvestingPro, Natera currently appears overvalued relative to its Fair Value estimate, positioning it among the most overvalued equities tracked by the platform.
Key Points:
- Executive Divestment Under Pre-Arranged Plan: Sheena Jonathan's sale of 3,150 shares for $836,898 was executed pursuant to a Rule 10b5-1 plan established in December 2025. This mechanism typically indicates pre-planned liquidity rather than reactive trading based on short-term market movements.
- Regulatory Milestones in International Markets: Natera's Signatera test has achieved critical regulatory approvals, including Class C certification under the EU In Vitro Diagnostic Regulation and approval from Japan's Pharmaceuticals and Medical Devices Agency. These developments are pivotal for the diagnostics sector, particularly in the oncology and minimal residual disease testing markets.
- Analyst Optimism on Volume Growth: Bernstein SocGen Group resumed coverage of Natera with an outperform rating. The firm highlighted the company's potential for increased volumes and improved reimbursement rates in minimal residual disease testing, identifying Japan as a key market driver for commercial activities expected by the end of 2026.
Risks and Uncertainties:
- Valuation Concerns: InvestingPro analysis indicates that Natera is currently overvalued relative to its Fair Value estimate. This discrepancy suggests potential downside risk if the stock price corrects toward intrinsic valuation metrics, impacting investors in the healthcare and biotechnology sectors.
- Dependence on Regulatory and Pricing Decisions: The commercial launch of the Signatera test in Japan is contingent upon pending pricing decisions. Delays or unfavorable pricing outcomes could impact revenue projections and market entry timelines for Natera and related diagnostics companies.
In addition to regulatory approvals, Natera has published data in JAMA Oncology demonstrating that its MRD test can predict the benefit of chemotherapy in liver cancer patients. The study involved 298 patients and was presented at the European Society for Medical Oncology Gastrointestinal Congress. The company has also partnered with Aveta Biomics for a Phase 3 clinical trial to evaluate a treatment for head and neck cancer, utilizing the Signatera test to monitor disease and treatment response.
Natera Inc. stock closed at 277.37, reflecting a 1.73% gain, with after-hours trading at 277.00. The stock's performance over the past year underscores significant investor interest in the company's diagnostic capabilities, particularly in the context of expanding regulatory approvals and clinical validation.